GlassScriptPhysician profile
Betty Thomas
NPI 1639708936
$4,556.18
in general payments reported to CMS, 2019-2025
33 companies · $2,160 in 2025
The $2,160 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.70 · 2023: $283 · 2024: $2,096 · 2025: $2,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,539.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $679.35 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $630.12 | 2023-2025 | Farxiga, Airsupra, Fasenra |
| Pfizer INC. | $501.74 | 2023-2025 | |
| Lilly USA, LLC | $403.30 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $319.65 | 2024-2025 | Spravato, Xarelto |
| Glaxosmithkline, LLC. | $270.68 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.90 | 2023-2025 | Jardiance, Stiolto Respimat |
| Exact Sciences Corporation | $154.97 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $149.38 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $129.68 | 2024-2025 | Edarbi, Azmiro |
| Averitas Pharma INC. | $115.51 | 2023-2025 | Qutenza |
| Shield Therapeutics INC | $109.28 | 2023-2024 | Accrufer |
| Intuitive Surgical, INC. | $93.02 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $85.96 | 2024-2025 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $65.13 | 2023-2024 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $61.71 | 2024-2025 | |
| Dexcom, INC. | $59.93 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Amgen INC. | $53.04 | 2023-2025 | Repatha, Otezla, Tezspire |
| Daiichi Sankyo INC. | $52.67 | 2025 | Injectafer |
| Medtronic, INC. | $51.76 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Phathom Pharmaceuticals, INC. | $43.72 | 2025 | Voquezna |
| Csl Behring | $38.84 | 2025 | Hizentra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.06 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $32.56 | 2024 | Quviviq |
| Cequr Corporation | $25.75 | 2024 | Cequr Simplicity |
| Sanofi Pasteur INC. | $23.84 | 2024 | |
| Merck Sharp & Dohme LLC | $21.56 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $17.62 | 2024 | |
| Novartis Pharmaceuticals Corporation | $17.53 | 2024 | |
| Organon LLC | $16.70 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.74 | 2025 | Xifaxan |
| Pacira Pharmaceuticals Incorporated | $15.26 | 2025 | Zilretta, Iovera |
| Esperion Therapeutics, INC. | $14.22 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betty Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.